CoChat

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab

Cho, Hyung, Shah, Chirag P, Weber, Marissa, Heier, Jeffrey S · 2013 · British Journal of Ophthalmology

The DOI matches its Crossref record; 22 of the 24 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To investigate the effect of aflibercept 2.0 mg in cases resistant to ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment. PURPOSE: To evaluate the anatomic and visual effect of intravitreal aflibercept 2.0 mg in cases of exudative age-related macular degeneration (AMD) with persistent fluid on optical coherence tomography (OCT) despite regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment at 1 and 6 months. METHODS: Retrospective review at Ophthalmic Consultants of Boston, Boston, Massachusetts, USA of exudative AMD cases with persistent fluid on regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment switched to intravitreal aflibercept 2.0 mg treatment and followed for 6 months. Tabulated data included details of prior treatments, best available visual acuity, central subfoveal thickness on registered spectral domain OCT before and after aflibercept injection centred on the anatomic fovea and macular description before and after aflibercept injection. RESULTS: A total of 353 eyes with exudative AMD were switched to aflibercept during the study period. Of these, 28 eyes in 28 patients had persistent fluid after an average of 20 regular ranibizumab/bevacizumab injections (range 7-37). At 1 month, 89% (25 eyes) showed anatomic improvement and 18% (five eyes) were dry after a single aflibercept injection. Central subfoveal thickness improved from 295 to 272 microns (p<0.001) after one aflibercept injection. After an average of 4.4 aflibercept injections (range 3-6) over 6 months, the central subfoveal thickness remained improved (274 microns, p=0.008); 64% (18 eyes) showed anatomic improvement and a quarter of eyes (25%, seven eyes) were dry. Visual acuity did not improve at 1 month (logarithm of minimum angle of resolution (logMAR) 0.54, Snellen 20/69, p=0.64) or 6 months (logMAR 0.57, Snellen 20/76, p=0.49). Treatment was well tolerated with no adverse events reported. CONCLUSIONS: A significant proportion of exudative AMD cases with persistent fluid on OCT despite regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment respond anatomically to aflibercept 2.0 mg. Visual acuity did not improve. Aflibercept may be beneficial anatomically in cases of exudative AMD treated with persistent fluid on ranibizumab and/or bevacizumab.

Overview

Integrity signals

Registry

Crossref · 10.1136/bjophthalmol-2013-303344

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Cited by

See all 170

Metadata

Authors
Cho, H., Shah, C. P., Weber, M., & Heier, J. S.
Affiliations
Ophthalmic Consultants of Boston (US)
Corresponding author
Heier, Jeffrey S
Venue
British Journal of Ophthalmology
Publisher
BMJ
Published
2013-06-13
Volume
97
Issue
8
Pages
1032-1035
ISSN
  • 0007-1161 (ISSN-L)
  • 1468-2079
OpenAlex
W2084462826
Cited by
161
References
24
Citations by year
2025: 4 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 9 · 2018: 14 · 2017: 21 · 2016: 31 · 2015: 32 · 2014: 31 · 2013: 4
FWCI
32.17
Type
journal article
Language
en
Open access
closed
Locations
  • British Journal of Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
aflibercept, neovascular age-related macular degeneration, ranibizumab, bevacizumab, treatment-resistant macular edema, intravitreal injection, visual acuity, anti-VEGF therapy, treatment switching, optical coherence tomography, fovea, retinal pigment epithelium
MeSH terms
Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Drug Resistance, Female, Follow-Up Studies, Humans, Male, Middle Aged, Recombinant Fusion Proteins, Retrospective Studies, Visual Acuity, Treatment Outcome, Retreatment, Receptors, Vascular Endothelial Growth Factor, Tomography, Optical Coherence, Wet Macular Degeneration, Drug Substitution, Intravitreal Injections, Subretinal Fluid, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. https://app.cochat.ai/papers/10.1136/bjophthalmol-2013-303344
The paper
Cho, H., Shah, C. P., Weber, M., & Heier, J. S. (2013). Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2013-303344

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.